Lin-Kun Shen

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 4

Top Topics

Radical Prostatectomy

Signaling Pathway

Top Venues

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Yang Liu, Chang-Lin Wang, Zhong-Qi Pang, Ke Gao, Lin-Kun Shen, Wan-Hai Xu, Ming-Hua Ren
Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12 , 1861. Journal of clinical medicine 13 (13) (2024)
Yang Liu, Chang-Lin Wang, Zhong-Qi Pang, Ke Gao, Lin-Kun Shen, Wan-Hai Xu, Ming-Hua Ren
Correction: Liu et al. Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. J. Clin. Med. 2023, 12 , 1861. Journal of clinical medicine 13 (13) (2024)
Yang Liu, Chang-Lin Wang, Zhong-Qi Pang, Ke Gao, Lin-Kun Shen, Wan-Hai Xu, Ming-Hua Ren
Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. Journal of clinical medicine 12 (5) (2023)
Yang Liu, Chang-Lin Wang, Zhong-Qi Pang, Ke Gao, Lin-Kun Shen, Wan-Hai Xu, Ming-Hua Ren
Endostatin 33 Peptide Is a Deintegrin α6β1 Agent That Exerts Antitumor Activity by Inhibiting the PI3K-Akt Signaling Pathway in Prostate Cancer. Journal of clinical medicine 12 (5) (2023)